U.S. President Donald Trump announces a tariff plan for imported generic drugs aimed at encouraging manufacturers to make products in the United States. Multiple reports say the measure starts with a tariff-free period for certain imported generics: from August 1, 2026, tariffs are set at 0% for two years. After that window, the tariff rises to 100% for the following one-year period, and then increases to 200% thereafter.
Other outlets describe the plan more narrowly, focusing on a 100% tariff beginning in August 2028, consistent with the start date of the higher duty level after the initial tariff-free phase. Several sources note the approach is intended to push non-patented or generic drugmakers to shift production onshore rather than rely on imports.
Indian drugmakers and suppliers discuss the potential implications for pricing, supply chains, and investment decisions, with some companies reassessing operations that depend on exporting to the U.S. Experts cited by TIME.com say the tariffs, if implemented, could affect the cost and availability of generic medications in the United States.
